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The relationship between circulating C-reactive protein concentrations and potential cytokine and receptor mediators (interleukin-6,
leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), soluble IL-6 receptor, soluble gp130, soluble TNF receptor,
interleukin-1 receptor antagonist and interleukin-8 (IL-8)) of this acute phase protein were examined in healthy subjects (n¼11) and
patients with non-small-cell lung cancer (n¼50). Leukaemia inhibitory factor and CNTF were below detection limits in all controls
and patients. C-reactive protein, interleukin-6, soluble gp130, soluble TNF receptor, interleukin-1 receptor antagonist and IL-8
concentrations were significantly elevated in cancer patients (Pp0.001). Cancer patients with elevated C-reactive protein
concentrations had greater concentrations of interleukin-6 (Po0.01) and interleukin-1 receptor antagonist (Po0.05). On regression
analysis only interleukin-6 was independently associated with C-reactive protein (r¼0.616, Po0.001). Interleukin-6 is an important
independent mediator of elevated C-reactive protein concentrations in patients with non-small-cell lung cancer.
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Non-small-cell lung cancer (NSCLC) is the most common cause of
cancer death in North America and Western Europe. Each year
in the United Kingdom there are almost 39000 new cases regis-
tered; only 7% are alive at 5 years (Cancerstats, 2004; www.
cancerresearchuk.org). Most patients present with advanced
inoperable disease, few are amenable to surgery and the results
of radiotherapy and chemotherapy are poor.
It has recently become clear that the systemic inflammatory
response, as evidenced by elevated circulating concentrations of C-
reactive protein, is an important factor in the progressive
nutritional decline of these patients and is a prognostic factor
independent of stage, performance status and treatment (Scott
et al, 2002; Forrest et al, 2003, 2004).
In the NSCLC patient the basis of the elevated C-reactive protein
concentrations is unclear. Previous work has shown a strong
positive association between interleukin-6 (IL-6) and C-reactive
protein concentrations (Yanagawa et al, 1995; Scott et al, 1996). A
number of other cytokines, which share structural homology and
signal through the gp130-Jak-STAT pathway, have, however, been
implicated in the elaboration of acute phase proteins in cancer
(Heinrich et al, 1998). For example, in vitro studies have shown
that leukaemia inhibitory factor (LIF) and ciliary neurotrophic
factor (CNTF) stimulate increased acute phase protein production
(Baumann et al, 1993). Additionally, there is evidence that soluble
receptor subunits involved in IL-6 signal transduction, the soluble
IL-6 receptor (sIL-6R) and the soluble gp130 receptor (sgp130),
may also be important in regulating IL-6 activity and the acute
phase protein response (Jones and Rose-John, 2002). Also, soluble
TNF receptor (sTNF-RII), IL-1 receptor antagonist (IL-1Ra) and
interleukin-8 (IL-8) have been reported to be associated with the
systemic inflammatory response in lung cancer patients (Yanagawa
et al, 1996; Simons et al, 1999; Alexandrakis et al, 2000).
The aim of the present study was to examine the relationship of
the inflammatory cytokines, cytokine receptors and circulating
concentrations of C-reactive protein in patients with NSCLC.
PATIENTS AND METHODS
Patients
Patients with a firm clinical or histological diagnosis of locally
advanced or metastatic advanced NSCLC from palliative care
centres in the West of Scotland were studied. Healthy subjects
individuals were recruited from volunteers of the palliative care
centres to serve as normal controls. The study was approved by the
local research and ethics committee. All patients and controls were
informed of the purpose of the study prior to entry and gave
written, informed consent.
Experimental design
A blood sample was collected for routine laboratory analysis of
white cell count, albumin and C-reactive protein. The minimum
detectable concentrations for C-reactive protein were 6mgl
 1. The
inter- and intra-assay variability of white cell count, albumin and
C-reactive, protein were less than 10%.
A further blood sample was taken and centrifuged and the
serum stored at  201C prior to analysis of inflammatory cytokines
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land receptors. Circulating concentrations of the proinflammatory
cytokines IL-6, LIF, CNTF and IL-8 and soluble receptors sIL-6R,
sgp-130, IL-1Ra and sTNF-RII were measured using an enzyme
linked immunosorbent assay (ELISA) technique. All samples were
measured in duplicate and the mean value used. The minimum
detectable concentrations were 2pgml
 1 for IL-6, 6.5pgml
 1 for
sIL-6R, 8ngml
 1 for sgp130, 1pgml
 1 for sTNF RII, 14pgml
 1 for
IL-1 Ra, 10pgml
 1 for IL-8, 8pgml
 1 for LIF and CNTF
(Quantikine ELISA, R&D Systems Europe Ltd, Abingdon, UK).
Inter- and intra-assay variability were less than 10% for all assays
used.
Statistical analysis
Data are presented as median and range. Inflammatory cytokine
and cytokine receptor concentrations below the threshold of
sensitivity of the respective assays were expressed as equal to this
threshold. Where appropriate, data were tested for statistical
significance using the Mann–Whitney U test. As the distribution
of C-reactive protein and the inflammatory cytokines and cytokine
receptor concentrations were skewed, they were logarithmically
transformed prior to stepwise multiple regression analysis for the
examination of independent associations with C-reactive protein
(SPSS version 11 Inc., Chicago, IL, USA).
RESULTS
The characteristics of the healthy controls and the NSCLC patients
are shown in Table 1. Age and sex were similar in healthy subjects
and patients. BMI and albumin were lower (Po0.05) and white cell
count (Po0.001) and C-reactive protein (Po0.001) were higher in
cancer patients compared with controls. Circulating concentra-
tions of CNTF and LIF were less than the detection limit of the
assay in all healthy subjects and cancer patients. Circulating
concentrations of IL-6, sgp130, sTNF-RII, IL-1Ra and IL-8 were all
significantly elevated in cancer patients compared with controls
(Po0.01).
NSCLC patients were grouped according to whether or not they
had evidence of a systemic inflammatory response (C-reactive
protein 410mgl
 1, Table 2). The groups were similar in terms of
age, sex, BMI, white cell count and circulating concentrations of
sIL-6, sgp130, sTNF-RII, and IL-8. In the inflammatory group
albumin concentrations were lower (Po0.05) and IL-6 (Po0.01)
and IL-1Ra (Po0.05) concentrations were higher. In the cancer
patients neither sIL-6R nor sgp130 concentrations were signifi-
cantly associated with either IL-6 or C-reactive protein concentra-
tions. In contrast, IL-6 concentrations were correlated with the
white cell count (r¼0.294, P¼0.038).
In the cancer patients who had detectable C-reactive protein
concentrations (n¼41), the relationship between log10 C-reactive
protein, log10IL-6, and log10IL-1Ra was examined in multiple linear
regression analysis. Only IL-6 was independently associated with
C-reactive protein (r¼0.616, Po0.001).
DISCUSSION
In the present study neither of the IL-6 type cytokines LIF and
CNTF were detected in the sera of normal healthy controls or
Table 1 Characteristics of healthy subjects and patients with NSCLC
Healthy controls (n¼11) NSCLC patients (n¼50) P-value
Age 66 (46–74) 64 (43–83) 0.894
Sex (M/F) 5/6 24/26 0.917
BMI 25.4 (22.4–28.9) 21.9 (14.8–64.2) 0.017
Albumin (gl
 1) 43 (41–46) 40 (28–44) o0.001
White cell count (10
9l
 1) 6.7 (4.1–8.4) 9.21 (5.1–23.5) o0.001
C-reactive protein (mgl
 1) o6( o6–o6) 26 (6–207) o0.001
IL-6 (pgml
 1) o2( o2–o2) 13 (o2–103) o0.001
SIL-6R (ngml
 1) 16.1 (14.9–24.2) 18.8 (7.8–46.0) 0.291
Sgp130 (ngml
 1) 234 (175–290) 298 (227–448) o0.001
sTNF-RII (ngml
 1) 1.5 (1.2–7.5) 2.9 (1.5–6.8) 0.001
IL-1Ra (pgml
 1) 286 (129–368) 539 (132–2129) o0.001
IL-8 (pgml
 1) o10 (o10–o10) 13.9 (o10–118) o0.001
Median (range).
Table 2 Characteristics of inflammatory and noninflammatory patients with NSCLC
C-reactive protein p10mgl
 1 (n¼14) C-reactive protein 410mgl
 1 (n¼36)
Median o6mgl
 1 Median 58mgl
 1 P-value
Age 61 (44–74) 66 (48–88) 0.119
Sex (M/F) 5/9 19/17 0.278
BMI 23.3 (19.7–31.0) 21.9 (14.8–64.2) 0.287
Albumin (gl
 1) 42 (38–47) 40 (28–46) 0.014
White cell count (10
9l
 1) 8.50 (5.60–18.87) 9.55 (5.10–23.50) 0.305
IL-6 (pgml
 1) 2.9 (2.0–22.2) 18.5 (2.0–103.0) 0.001
SIL-6R (ngml
 1) 23.3 (14.0–30.7) 18.8 (7.8–46.0) 0.216
Sgp130 (ngml
 1) 280 (218–330) 298 (227–448) 0.572
sTNF-RII (ngml
 1) 2.5 (1.5–5.1) 3.2 (1.5–6.8) 0.122
IL-1Ra (pgml
 1) 378 (234–902) 724 (132–2128) 0.016
IL-8 (pgml
 1) o10.0 (o10.0–90.6) 13.9 (o10.0–118.0) 0.152
Median (range).
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rodent studies to induce an acute phase protein response and
weight loss (Mori et al, 1991; Xu et al, 1998) our results are
consistent with the largely undetectable levels reported in patients
with rheumatoid arthritis (Okamoto et al, 1997). We cannot
preclude, however, the possibility that these cytokines may be
active systemically at concentrations below the sensitivity limit of
current assays.
It has been proposed that soluble receptor subunits may be
important in regulating IL-6 activity and C-reactive protein
production (Jones and Rose-John, 2002). In the present study,
however, neither sIL-6R nor sgp130concentrations were signifi-
cantly different between the inflammatory and noninflammatory
cancer patients. Furthermore, neither sIL-6R nor sgp130 concen-
trations were significantly associated with either IL-6 or C-reactive
protein concentrations in the cancer patients. Although measure-
ment of soluble forms of interleukin-6 receptor and gp130 provide
a total evaluation of the active concentrations of these mediators,
both soluble receptor components exist in several forms and the
ELISA determinations do not preclude specific changes in
individual sgp130 or sIL-6R isoforms.
In the present study only IL-6 and IL-1Ra were significantly
associated with C-reactive protein concentrations in patients with
NSCLC. By multiple regression analysis, however, only IL-6 was
independently associated with C-reactive protein concentrations.
The results of the present cross-sectional study do not preclude the
relationship between interleukin-6 and C-reactive protein simply
reflecting the simultaneous release of these factors. Nevertheless,
taken together these results would suggest interdependence and
that C-reactive protein, a routinely available and well-standardised
clinical laboratory measurement, is a useful surrogate measure of
interleukin-6 activity in patients with NSCLC.
The source of IL-6 in patients with NSCLC remains uncertain
since both a variety of host cells and the tumour cells have been
shown to produce IL-6. In the present study, IL-6 was only weekly
correlated with white cell count in the patients with NSCLC. This
may suggest additional sources of IL-6 in these patients. For,
example, some lung cancer cell lines have been shown to produce
IL-6. Indeed, there is some evidence that IL-6 produced by such
tumour cells may act as an autocrine growth factor promoting the
survival and invasion of the tumour into surrounding tissue (To
et al, 2002).
To date, there have been few attempts to moderate the systemic
inflammatory response in patients with cancer. Previous work has
used a broad-brush approach with nonspecific anti-inflammatory
agents (Lundholm et al, 1994; McMillan et al, 1999). The value of
the present study is that it clearly identifies IL-6 from other
candidate mediators of the increase in C-reactive protein
concentration in a homogenuous cohort of cancer patients.
It also suggests that specific targeting of IL-6 signalling may be
appropriate in patients with NSCLC. It is therefore of interest that
anti-interleukin-6 receptor antibody has been shown to be
clinically beneficial for the treatment of arthritis and Crohn’s
disease and its action is associated with the suppression of C-
reactive protein (Nishimoto et al, 2004; Ito et al, 2004).
In summary, interleukin-6 is an important independent
mediator of elevated C-reactive protein concentrations in patients
with NSCLC.
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